In:
European Journal of Haematology, Wiley, Vol. 94, No. 2 ( 2015-02), p. 130-137
Abstract:
A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy ( CCRT ) plus consolidation chemotherapy for patients with stage I / II nasal natural killer/T‐cell lymphoma ( NKTCL ). Patients and methods Patients with newly diagnosed, measurable stage I / II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cG y radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov ( NCT 00292695). Results Thirty‐three patients received CCRT , and 29 patients received two cycles of consolidation DVIP after CCRT . Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI , 68–95%) and 63% (95% CI , 46–79%), respectively. The 2‐yr and 5‐yr progression‐free survival rate for intention‐to‐treat population was 64% (95% CI , 47–80%) and 60% (95% CI , 39–73%), respectively; while the corresponding overall survival rate was 73% (95% CI , 57–88%) and 66% (95% CI , 50–83%), respectively. The most common treatment‐related grade 3/4 adverse event was leukopenia (85%). Conclusion Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL .
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2015.94.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2027114-1
Bookmarklink
